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The Ascend West and Central Africa programme, funded by the UK Foreign, Commonwealth and Development
Office (FCDO) is supporting integrated preventative chemotherapy for up to five neglected tropical diseases
(NTDs), including intestinal worms, lymphatic filariasis, river blindness, trachoma and schistosomiasis. The pro-
gramme is implemented across 13 countries by a consortium of four leading international development part-
ners: Sightsavers, Liverpool School of Tropical Medicine, Schistosomiasis Control Initiative Foundation and Mott
Macdonald. This paper presents messages learnt from country assessments that took place prior to the global
outbreak of coronavirus disease 2019 (COVID-19). Thesemessages remain relevant post-COVID-19, with greater
priority being given to the challenges for national NTD programmes in continuing to deliver mass drug admin-
istration (MDA) during the pandemic. Stakeholder coordination from the earliest stages of the pandemic has
occurred at two levels: in the first mile with global partners of the NTD Supply Chain Forum and in the last mile
with implementing partners in each country. This has been instrumental to manage delayed MDA, including the
impact delays have on the shipment of NTD donated drugs and the distribution of stock held in country. The
Ascend West and Central Africa programme is supporting countries with the resumption of MDA through a risk
assessment and mitigation action (RAMA) process.
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Introduction
Health system strengthening is a key component of the Ascend
West and Central Africa programme, which encompasses build-
ing supply chain capacity to improve last mile drug availability
and data. In this context, the last mile refers to the in-country
procedures leading up to the final point of distribution to com-
munities. Overall, Ascend aims to positively impact the sustain-
ability of national neglected tropical disease (NTD) programmes.
Building supply chain capacity within ministries of health aims to
address the challenges faced by national NTD programmes.
Integrated preventative chemotherapy and transmission con-
trol (PCT) is the principal strategy promoted by the World Health
Organisation (WHO) for the safe, simple and effective control
and elimination of a group of the most prevalent NTDs. Treat-
ment is delivered via mass drug administration (MDA) to entire
at-risk populations or to specific at-risk groups, such as school-
age children.1 Record-breaking commitment for drug donation
by pharmaceutical companies to endemic countries and the ser-
vice delivery model of volunteer community drug distributors
(CDDs) enables cost-effective, large-scale PCT programmes to be
delivered. Furthermore, the WHO estimate that at least 1.76 bil-
lion people still require interventions against NTDs.2
To date,more than1 billion people have received treatment for
at least one NTD.3 However, increased volume of drug donations
alone is neither sustainable nor sufficient to control and elimi-
nate NTDs. How to integrate a comprehensive approach, which
combines MDA with on-demand access to treatment, with NTDs
packaged into universal health coverage and national health sys-
tems, is a challenge that needs further research and action.4
To be fully effective, national health systems require capac-
ity at all levels, especially in the last mile of the supply chain.
For low- and middle-income countries (LMICs), the infrastruc-
ture and distribution networks, political and environmental con-
text, as well as the involvement of many stakeholders and part-
ners, is particularly complex. It is hindered by a lack of human
resources, adequate funding and physical infrastructure such as
road networks and storage facilities. The risks of not address-
ing these challenges include stock-outs, wastage, loss and/or
theft of tablets, and potentially delayed or missed treatment.
Furthermore, effective management of the NTD supply chain
directly impacts on the costs and effectiveness of national
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NTD programmes, supporting elimination targets and value-for-
money objectives. Collaboration and investment in the NTD sup-
ply chain generates significant benefits, as demonstrated in the
first mile though a unique public-private partnership (the NTD
Supply Chain Forum). Furthermore, the role of the forum and its
resilience have been tested andaffirmedmost recently during the
unprecedented times of the coronavirus disease 2019 (COVID-
19) pandemic.5
Focus on supply chain capacity and sustainability is consistent
with the WHO Road Map for NTDs 2021–2030 and its compan-
ion document, the WHO NTD Sustainability Framework for Action
(Box 1), which aims to address the gaps in elimination of NTDs.
Access, logistics and integration are three of the areas highlighted
for crucial action. These are intrinsically linked to health system
strengthening through improving the capacity to deliver interven-
tions on the ground.
Box 1. Supply chain extracts from key global NTD documents
WHO Road Map for NTDs 2021–20302
 An integrated approach to NTD activities is expected to result in
better health outcomes, greater cost efficiency and effectiveness
and better programme management
 Integration of the NTD supply chain with national medicine sup-
ply networks
 Integrated approaches to NTDs can and should be main-
streamedwithin various components of national health systems; …
delivery of medicines should be coordinated through national
medicines supply and logistics systems
 Remaining challenges of improving ‘last-mile’ delivery, integrat-
ing provision of NTD medicines and products and improving the
transparency of the supply chain
 Need for a strong, responsive supply chain
WHO NTD Sustainability Framework for Action 2021–20306
Sustainability will depend on the continuity of these [PC-NTD drug]
donations in the short term, and a transition to country-procured
and financed products in the medium to long term. Leveraging the
strengths of both systems, including forecasting and distribution
functions, to improve the supply chain for NTDmedicines and prod-
ucts is critical to sustainability. In countries where the NTD supply
chain is integrated into the national supply chain, understanding
the supply chain structures that facilitate or hamper sustainability,
including how national systems incorporate newmedicines, will be
necessary.
Materials and Methods
The Ascend programme is supporting national NTD programmes
to develop and implement NTD supply chain capacity building
plans in countries where the programme supports MDA. From
April 2019 to March 2020, during the first year of the programme
and prior to the onset of the COVID-19 pandemic, assessments
took place in five countries: Chad, Ghana, Guinea Bissau, Liberia
and Sierra Leone. These countries were selected based on vari-
ous factors, including overall volume of NTD donated drugs to the
country, representation of varying degrees ofmaturity in national
NTD programmes and an ability to combine the field visits with a
health system strengthening assessment.
An assessment tool was used to ensure consistent data col-
lection and thematic analysis. The approachwas alignedwith the
Dalberg Sustainability tool used for health system strengthening
assessments. Focus areas (Table 1) were based on the technical
expertise of the supply chain capacity building team and covered
supply chain considerations for donated drugs found in the ITI
Zithromax Guide for Programme Managers.7
Table 1. Focus areas for supply chain capacity assessment
Assessment focus areas
 Developing guidelines and standard operating
procedures
 Owning procurement and supply systems
 Drug supply distribution network
 Staff and organisational support
 Planning and forecasting
 Data management and logistics management
information system
 Inventory control procedures
Warehousing and storage
 Quality assurance
 Transport and distribution (in-country)
 Reverse logistics
 Morbidity management and disease prevention
 Monitoring and evaluation and reporting
 Mass drug administration training
Assessments were led by the consortium’s supply chain
capacity building team with the support of country office staff
and national NTD programme staff. Preceding field visits, an
online review of the literature relevant to NTDs, as well as the
national health system and the supply chain in each country for
the last 3–5 years, was conducted. During field visits, semistruc-
tured key informant interviews (KIIs) were held with Ministry of
Health and partner staff at national level and, where possible,
with NTD stakeholders at health facilities (regional/provincial, dis-
trict and subdistrict levels). KIIs focused on in-country procedures
and on the lastmile of the NTD supply chain. Health facilities were
selected primarily based on accessibility within the timeframe for
the field visit. Interviewees were selected based on their role and
responsibility at the health facility and/or involvement with the
NTD programme (e.g. on MDA campaigns). Health facilities have
limited staff, and thereforemany interviewees also support other
health programmes. This consultative approach across different
levels gave voice to the diverse stakeholders of the NTD supply
chain. It gave those working at national level and delivering on
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Meetings were also held with representatives of other national
health programmes, development partners and the national
pharmaceutical board and/or School of Pharmacy (where
available). These meetings helped the team to identify initiatives
and opportunities in thewider health systemand supply chain for
cross learning and/or collaboration.
Results
Assessments provided valuable information on where to build
capacity and on how to address challenges in the NTD supply
chain. The following sections of the paper summarise what was
learnt in five of the focus areas across the countries assessed.
While the assessment primarily focused on PCT (preven-
tive chemotherapy and transmission control)-NTD diseases, the
results can be extrapolated to NTD case management diseases
as the findings and recommendations relate to measures that
address the strengthening of national systems. A key difference
in the health supply chain for PC-NTD and case management
treatments is the source of medicines. While PC drugs are sup-
plied vertically through pharmaceutical donation programmes,
medicines for case management can typically be found in the
existing health system. Irrespective of supply sources and dis-
tribution modes, application of good supply chain management
practices is required. An example is planning and forecasting,
which requires granular data on treatment population and stock
quantities.
Planning and forecasting
Planning for MDA is a comprehensive process, of which drug
quantification is a key element. Drug quantification needs to
occur up to a year before drug treatments, in line with drug
donation programmes and joint application processes. Typically,
national census data plus the estimated annual percentage of
population growth is used to assess the required number of treat-
ments. This information is often outdated (by several years or
even decades) andmaynot accurately account for changing pop-
ulation dynamics. For example, cross-border movement, internal
migration of seasonal workers and cross-district travel by school-
age children.
Last mile distribution planning occurs for each treatment
round. One country highlighted an improvement in stock use by
applying the previous year’s consumption data plus a buffer per-
centage to allocate stock.
Drug supply distribution network, data management
and logistics management information system
Distribution is a key step in the supply chain cycle, which starts
preshipment and runs through to disposal. Figure 1 provides an
overview of stages with key responsibilities and activities as an
example. Data on leftover stock from previous treatment rounds
are not easily retrievable, particularly from lower levels of the
health system. Typically, there is an absence of an electronic
logistics management information system (eLMIS) and MDA
treatment records are kept by paper copies. The current verifica-
tion practices of national NTD programmes are often resource-
intensive, yet data on leftover stock are a requirement for annual
drug applications.
At the time of assessment, all the countries assessed lacked
integrated and reliable systems for stock management, track-
ing and reporting. However, countries are progressing at var-
ious stages with implementing (or expanding) eLMIS’. Rea-
sons for lack of, or slow, progress can be financial as well
as practical. For example, these systems require technology
assets and support, reliable data access and human resource
training.
The assessment found several scenarios. Some countries have
an electronic system in place at the central medical stores (CMS)
yet not at subnational level; national and subnational systemsare
different and not integrated; data systems and tools used by the
NTD programme are operated separately to any national health
and logistics information systems; and/or the process is paper-
based.
Last mile drug distribution may be carried out by the national
NTD programme. For example, drugs may be distributed to NTD
supervisors through cascade training before MDA, or the NTD
focal person may collect drugs from the medical stores. In
one country it was found that the LMIS could not account for
this process. The NTD focal person is not considered a ‘goods
recipient’ in the system and as a result the system shows the
drugs as ‘in stock’ after collection. In another country assessed,
the LMIS consists of a set of paper-based forms and Microsoft
Excel templates (Microsoft Corporation, Redmond, Washington,
United States) do not integrate with any systems at the medical
stores.
Data quality impacts the ability of national NTD programmes
to plan and forecast, submit drug applications and allocate drug
stocks, aswell as learn fromprevious treatment rounds. This is rel-
evant to all countries assessed irrelevant of maturity and/or size,
although issues are heightened by paper-based systems and/or
vast geographical coverage.
Reverse logistics (and accountability for leftover stock)
Countries in receipt of donated drugs are required to keep track of
and report on stock in their joint application package submission
for the following year’s request for drugs. Therefore, retrieval of
leftover stock following MDA (referred to as reverse logistics) is
critical for NTD programmes.
NTDprogrammesdonot have sustainable solutions for reverse
logistics. Lack of equipment and poor infrastructure are known
challenges for all countries assessed. The assessment also found
that reverse logistics can rely on NTD staff at all levels, from NTD
supervisors retrieving leftover stock from community-directed
distributors to NTD national staff carrying out stock counts post-
MDA. In one country, theNTDprogrammeexpressed concern that
the time and costs of monitoring activities by national staff was
a suboptimal practice.
Reverse logistics is not unique to NTD donated drugs, rather
it is a common requirement for all health commodities. Mea-
sures to improve compliance with procedures and/or reduce the
burden of monitoring need to be further explored. Opportunities
can be explored with the national health supply system and/or
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Figure 1. An example of an overview of the NTD supply chain for PCT donated drugs including key responsibilities and activities.
Staff and organisational support
Assessments highlighted that NTD programmes have differ-
ing levels of support for supply chain management at the
national level. For most national NTD programmes, the sup-
ply chain responsibilities are divided among NTD team mem-
bers, rather than allocated as a separate role to a trained
person. Some NTD programmes have a pharmacist within the
national team. In all countries assessed, staff training for supply
chain management remains a challenge regardless of the team
structure.
A key recommendation for NTD programmes, which benefit
from an NTD pharmacist within the team, is to raise the pro-
file of NTDs within the national health system by raising the
profile of the NTD pharmacist across the ministry, including the
procurement and supply chain unit and the pharmacy board.
This can be achieved through the NTD pharmacist taking an
active role at the national level, to represent the NTD programme
and facilitate integration of the programme into national sys-
tems such as its management information systems (LMIS for
logistics and Health Management Information System (HMIS)
for health).
Discussion
As a result of the assessment findings and recommendations,
the Ascend team contributes at the global level through part-
nerships such as the NTD Supply Chain Forum and the technical
working group led by Expanded Special Project for Elimination of
Neglected Tropical Diseases (ESPEN) Act to End NTD programme.
This has provided opportunities to pool technical resources and
avoid duplication of efforts, for example, on developing standard
operating procedures (SOPs) for NTD supply chain management.
The Ascend progamme is supporting several countries to review
and provide feedback on the ESPEN SOPs, to adapt and adopt
them to be country-specific and enhance the established MDA
cascade training approach.
While there may be a desire to have one solution that can be
easily replicated across all countries, there is no one-size-fits-all
approach. Recommendations need to be contextualised for each
country and aligned with health system-strengthening strate-
gies. Ownership is with NTD programme managers, who may
look to their counterparts in other health programmes and across
the ministry, as well as to partners, to support implementation.
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Conclusion
The supply chain assessments supported through the Ascend
West and Central Africa programme have highlighted key lessons
in the last mile of the NTD supply chain. There is an oppor-
tunity for NTD programmes and national health supply chain
teams to better understand how each other works and reinforce
the role of qualified pharmacists and pharmacists’ technicians in
the NTD supply chain. Integration of the NTD supply chain into
national health systems should be an explicit objective of the NTD
master plan at country level. An area that can be improved first is
SOPs. This focus is shared at the global level through NTD partner-
ships: the NTD Supply Chain Forum and technical working groups
of ESPEN and United States Agency for International Develop-
ment Act to End NTD programme. Other opportunities include
enhancing the establishedMDA cascade training aswell as devel-
oping specific continuing professional development training for
health workers.
Supply chain is recognised as a key element in the WHO
‘building blocks’ for health systems. The ongoing COVID-19
pandemic highlights the significant pressure faced by min-
istries of health. Building capacity in the last mile of the
NTD supply chain means including hard to reach communities,
which positively impacts strengthening of the national health
system.
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